David Ben Menahem

Title: Innovations of David Ben Menahem

Introduction

David Ben Menahem is an accomplished inventor based in St. Louis, MO (US). He has made significant contributions to the field of glycoprotein hormones, holding two patents that showcase his innovative work. His research has implications for both medical and scientific advancements.

Latest Patents

David's latest patents include "Cystine depleted glycoprotein hormones" and "Single chain glycoprotein hormones comprising two beta and one alpha." The first patent describes single-chain forms of glycoprotein hormones LH, FSH, TSH, or CG that lack at least one disulfide bridge. These forms are useful as agonists or antagonists of the native glycoprotein hormones. The second patent discloses single-chain agonists and/or antagonists of glycoprotein hormones, which are essential for various biological applications.

Career Highlights

Throughout his career, David has demonstrated a commitment to advancing the understanding of glycoprotein hormones. His work has been recognized for its potential to influence therapeutic approaches in medicine. He is affiliated with Washington University, where he continues to contribute to research and innovation.

Collaborations

David has collaborated with notable professionals in his field, including Irving Boime. These partnerships have enhanced the scope and impact of his research.

Conclusion

David Ben Menahem's innovative work in glycoprotein hormones exemplifies the intersection of research and practical application. His patents reflect a dedication to advancing scientific knowledge and improving health outcomes.